MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Berkeley Lights Total Liabilities 2011-2026 | BLI
Annual Total Liabilities Berkeley Lights
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 84 M | 79 M | 54.9 M | 47.2 M | 36.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 84 M | 36.2 M | 60.3 M |
Quarterly Total Liabilities Berkeley Lights
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67.1 M | 143 M | 84 M | 76.7 M | 74.3 M | 72.7 M | 79 M | 81 M | 63.9 M | 60.6 M | 54.9 M | 54.9 M | 54.9 M | 54.9 M | 47.2 M | 47.2 M | 47.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 143 M | 47.2 M | 68.4 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
38.7 M | $ 2.8 | -3.69 % | $ 158 M |  China |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
855 M | $ 80.89 | -1.35 % | $ 1.56 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Amgen
AMGN
|
50 B | $ 341.41 | -0.45 % | $ 183 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
90.7 M | - | - | $ 1.01 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.68 | 3.88 % | $ 16.8 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.23 | -1.01 % | $ 7.77 B |  Australia |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Aptose Biosciences
APTO
|
14.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brickell Biotech
BBI
|
6.5 M | - | -5.38 % | $ 6.06 M | USA |
 |
Biogen
BIIB
|
11.3 B | $ 177.21 | 0.61 % | $ 25.8 B | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Beam Therapeutics
BEAM
|
370 M | $ 28.43 | -2.94 % | $ 2.34 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
1.29 B | $ 224.26 | 0.14 % | $ 5 B |  Danmark |
 |
Athira Pharma
ATHA
|
13.9 M | - | - | $ 269 M | USA |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
3.12 B | $ 115.04 | -1.49 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 9.65 | - | $ 1.52 B | Britain |
 |
Arrowhead Pharmaceuticals
ARWR
|
106 M | $ 68.78 | -0.5 % | $ 9.2 B | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
CASI Pharmaceuticals
CASI
|
30.3 M | $ 1.01 | 1.6 % | $ 137 M | USA |
 |
Catalyst Biosciences
CBIO
|
38.1 M | $ 9.79 | -3.55 % | $ 644 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
243 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 4.0 | -3.61 % | $ 8.7 B |  Israel |
 |
Amneal Pharmaceuticals
AMRX
|
3.32 B | $ 14.0 | -0.78 % | $ 4.33 B | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Cerus Corporation
CERS
|
144 M | $ 2.28 | -1.94 % | $ 421 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Baudax Bio
BXRX
|
34.3 M | - | 0.59 % | $ 63 K | USA |